2023-05-04 17:56:06 ET
- NextCure press release ( NASDAQ: NXTC ): Q1 GAAP EPS of -$0.58 beats by $0.04 .
- Cash, cash equivalents, and marketable securities as of March 31, 2023, were $145.5 million as compared to $159.9 million as of December 31, 2022. The decrease of $14.4 million was primarily related to cash used to fund operations, and cash used to purchase fixed assets.
- NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into mid-2025.
For further details see:
NextCure GAAP EPS of -$0.58 beats by $0.04